Enhanc3D Genomics, a company identifying novel targets with the 3D genome, has appointed Hazel Jones as CEO after a successful six-month tenure as interim CEO and COO.
As COO and interim CEO Hazel has overseen the company's global business operations and held responsibility for executing its strategic vision for commercial and academic partnerships. She has played a leading role in transitioning the Company's 3D genomics platform from development to practical application in R&D.
With over a decade of senior leadership experience in oncology research, Hazel brings expertise in all phases of drug development, driving operational change to advance disease diagnosis and treatments.
Prior to joining Enhanc3D Genomics as COO in November 2023, Hazel held various roles within AstraZeneca, including Executive Product Director of Clinical Data, and Head of Business Planning and Operations in Oncology R&D. She was also previously Head of Combination Therapies at Cancer Research UK.
Enhanc3D Genomics has established a genome-wide 3D-genome mapping technology, GenLink3D, which provides profound insights into long-distance gene regulation and disease pathways, demystifying the non-coding genome. GenLink3D profiles 3D genome folding at high resolution and over long distances, for all genes and their enhancers, identifying cell-type specific contacts and providing complete genome connectivity to disease pathways for the discovery of novel targets and biomarkers.
Dr Chris Torrance, Chairman of the Board of Directors, Enhanc3D Genomics, said: “We're thrilled to officially appoint Hazel as CEO. Her guidance as COO and interim CEO has been instrumental in driving Enhanc3D Genomics’ global operations, forming new connections and developing existing strategic partnerships. On behalf of the Board, I congratulate Hazel and look forward to continuing to work with her during this exciting phase for the Company.”